Stocktoria
Jazz Pharmaceuticals plc JAZZ
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-01-18
Jazz Pharmaceuticals plc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% |
| Net margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% |
| FCF margin | 30.4% | 33.4% | 27.9% | 34.0% | 24.3% |
| Return on assets | -3.1% | 4.7% | 3.6% | -2.1% | -2.7% |
| Return on equity | -8.2% | 13.7% | 11.1% | -7.3% | -8.3% |
| Debt / equity | 1.24× | 1.49× | 1.53× | 1.86× | 1.53× |
| Current ratio | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 |
| Revenue growth | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% |
Source: SEC EDGAR filings · CIK 0001232524 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.